A Description of Warfarin and NOAC Utilization Patterns Including Initiation, Switching, and Discontinuation
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Dabigatran etexilate (Primary) ; Anticoagulants; Warfarin
- Indications Atrial fibrillation; Stroke; Thromboembolism
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 01 Dec 2017 Status changed from recruiting to completed.
- 30 Oct 2017 Planned End Date changed from 30 Oct 2017 to 31 Oct 2017.
- 30 Oct 2017 Planned primary completion date changed from 30 Oct 2017 to 31 Oct 2017.